Wolters Kluwer announces two senior executive appointments
17.4.2024 15:00:00 EEST | Business Wire | Press release
Wolters Kluwer, a global leader in information, software, and services for professionals, today announced Atul Dubey as General Manager of its Finance, Risk and Regulatory Reporting (FRR) business, part of its Corporate Performance & ESG (CP & ESG) division. Suzanne Konstance will succeed Dubey as General Manager of Wolters Kluwer Legal & Regulatory U.S, part of the company’s Legal & Regulatory division, effective May 1.
Karen Abramson, CEO of Wolters Kluwer CP & ESG, commented: “Atul’s deep understanding of the financial regulatory and risk landscape will be critical strengths as he takes this global leadership role for Wolters Kluwer FRR, driving growth and relentless innovation for our clients.”
Wolters Kluwer FRR’s award-winning OneSumX suite of solutions support financial institutions through innovative technology that enables and empowers clients to stay compliant with everchanging regulatory requirements, manage uncertainty through financial risk management offerings and drive efficiency.
“Serving over 800 customers in 40 countries, OneSumX for FRR has a significant global role in the financial services ecosystem,” Dubey commented. “I look forward to working with Karen and the talented team to drive product enhancement and innovation, delivering value to our clients, partners and regulators.”
Dubey joined Wolters Kluwer in 2016 as Chief Strategy Officer, with a strong background in institutional banking, having held senior leadership roles at Citigroup, S&P Global and Booz Allen.
Martin O’Malley, CEO of Wolters Kluwer Legal & Regulatory: “I am grateful for Atul’s incisive leadership, which has seen our solutions, services and customers thrive during a period of unparalleled transformation for our industry. At the same time, I am excited to welcome Suzanne to our division. Her deep industry expertise, commitment to innovation and experience in creating vibrant team cultures will continue to push our U.S. business to new heights.”
Konstance held leadership positions in Wolters Kluwer for eight years, in which she built a strong track record in product management, strategy and go-to-market. She most recently served as Vice President & Segment Leader of Lien Solutions for the Wolters Kluwer Compliance Solutions business unit – a part of the company’s Financial & Corporate Compliance (FCC) division. She successfully engaged in launching AI-enabled products to transform the business while managing to achieve an above-market growth rate. Prior to joining Wolters Kluwer, Konstance held senior roles at Pitney Bowes, Citibank, and MetLife.
“By combining unparalleled domain expertise with the latest AI-driven technology, Wolters Kluwer Legal & Regulatory U.S. is uniquely positioned to help today’s legal professionals achieve measurable efficiencies and gain valuable insights,” Konstance said. “I am eager to begin collaborating with this dynamic team as we chart a path toward continued growth.”
Wolters Kluwer Legal & Regulatory U.S. is a leading provider of information, business intelligence, and regulatory and legal workflow solutions for legal, corporate, and compliance professionals across several industries. Legisway, Wolters Kluwer’s award-winning and all-in-one SaaS legal information and contract management solution for corporate legal departments, recently launched new AI-enhanced functionality, accelerating the contract review process by enabling legal departments to effortlessly query their contracts using advanced natural language processing.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417358923/en/
Contact information
Media
Sarah Whybrow
Associate Director, External Communications
Corporate Performance & ESG
Wolters Kluwer
Mob: +44 7855 186713
sarah.whybrow@wolterskluwer.com
Frank Ready
Manager, External Communications
Legal & Regulatory
Wolters Kluwer
Office: 717-205-3647
Email: Frank.Ready@wolterskluwer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom